Clinical and morphological practices in the diagnosis of transplant-associated microangiopathy: a study on behalf of Transplant Complications Working Party of the EBMT

[1]  C. Lengerke,et al.  High mortality in hematopoietic stem cell transplant-associated thrombotic microangiopathy with and without concomitant acute graft-versus-host disease , 2018, Bone Marrow Transplantation.

[2]  S. Davies,et al.  Circulating dsDNA, endothelial injury, and complement activation in thrombotic microangiopathy and GVHD. , 2017, Blood.

[3]  C. Hofmeister,et al.  Eculizumab therapy in adults with allogeneic hematopoietic cell transplant-associated thrombotic microangiopathy , 2016, Bone Marrow Transplantation.

[4]  K. Myers,et al.  New approaches in the diagnosis, pathophysiology, and treatment of pediatric hematopoietic stem cell transplantation-associated thrombotic microangiopathy. , 2016, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[5]  M. Tanimoto,et al.  Treatment of thrombotic microangiopathy after hematopoietic stem cell transplantation with recombinant human soluble thrombomodulin , 2016, Transfusion.

[6]  J. Lesesve,et al.  Fragmented red cells reference range for the Sysmex XN®‐series of automated blood cell counters , 2015, International journal of laboratory hematology.

[7]  J. Bay,et al.  Use of Eculizumab in Patients With Allogeneic Stem Cell Transplant-Associated Thrombotic Microangiopathy: A Study From the SFGM-TC , 2015, Transplantation.

[8]  W. Hogan,et al.  Outcomes of plasma exchange in patients with transplant‐associated thrombotic microangiopathy based on time of presentation since transplant , 2015, Journal of clinical apheresis.

[9]  J. Khoury,et al.  Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults. , 2014, Blood.

[10]  J. González-Porras,et al.  Analysis of incidence, risk factors and clinical outcome of thromboembolic and bleeding events in 431 allogeneic hematopoietic stem cell transplantation recipients , 2013, Haematologica.

[11]  S.‐H. Lee,et al.  ICSH recommendations for identification, diagnostic value, and quantitation of schistocytes , 2012, International journal of laboratory hematology.

[12]  S. Davies,et al.  Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation-associated thrombotic microangiopathy. , 2011, Blood.

[13]  T. Lecompte,et al.  Evaluation of schistocyte monitoring after haematopoietic stem cell transplantation , 2011, International journal of laboratory hematology.

[14]  B. Cho,et al.  Validation of Recently Proposed Consensus Criteria for Thrombotic Microangiopathy After Allogeneic Hematopoietic Stem-Cell Transplantation , 2010, Transplantation.

[15]  James W. Young,et al.  Chronic kidney disease, thrombotic microangiopathy, and hypertension following T cell-depleted hematopoietic stem cell transplantation. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[16]  F. Baron,et al.  Comparison of thrombotic microangiopathy after allogeneic hematopoietic cell transplantation with high-dose or nonmyeloablative conditioning , 2010, Bone Marrow Transplantation.

[17]  C. Alpers,et al.  Renal thrombotic microangiopathy after hematopoietic cell transplant: role of GVHD in pathogenesis. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[18]  A. Gratwohl,et al.  Transplant-associated microangiopathy (TAM) in recipients of allogeneic hematopoietic stem cell transplants , 2005, Bone Marrow Transplantation.

[19]  D. Srivastava,et al.  Hemolytic uremic syndrome after bone marrow transplantation: clinical characteristics and outcome in children. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[20]  R. Soiffer,et al.  Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[21]  R. Soiffer,et al.  Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[22]  M. Czuczman,et al.  Thrombotic Microangiopathy after Allogeneic Blood and Marrow Transplantation Is Associated with Dose-Intensive Myeloablative Conditioning Regimens, Unrelated Donor, and Methylprednisolone T-Cell Depletion , 2004, Transplantation.

[23]  A. Kiani,et al.  Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[24]  J. Moake,et al.  Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. , 2007, Haematologica.